InsightsAI-driven drugmakers fuel wave of cross-border deals in ChinaInvestors are reassessing de novo drug design as firms close major BD transactions. 5 mins read
Chair Zhao Yan is steering the company away from hype-driven marketing, investing in synthetic biology to rebuild growth and credibility. FeaturesAfter years of “sleep,” Bloomage faces biotech’s hard realities with a bet on science9 mins read
After inking an USD 8.4 billion deal with BMS, the founder says Biokin’s next chapter is about efficiency, innovation, and going global. FeaturesThe “richest man on the STAR Market” wants more than wealth: Biokin’s chairman sets sights on MNC status11 mins read
The company hopes to stand out with Diabegone, a diabetes treatment that lasts longer than competing drugs from companies like Novo Nordisk and Eli Lilly. NewsInnogen bets on longer-lasting GLP-1 drugs to stand out in crowded field4 mins read
As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets. InsightsAfter Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line?6 mins read
After a dry spell, the city’s biotech scene is showing fresh signs of life as investors pay attention again. NewsLeads Biolabs’ IPO points to biotech rebound in Hong Kong5 mins read
New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens. InsightsHong Kong biotech enters its second act with a licensing supercycle14 mins read
The Silicon Valley entrepreneur has turned his body into a living experiment in a bid to reframe longevity as a solvable problem. FeaturesBryan Johnson: The man trying to engineer longevity into the human condition18 mins read
The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best. FeaturesEverest Medicines targets global expansion with proprietary, AI-driven mRNA platform7 mins read